Core Viewpoint - The announcement from Huili Pharmaceutical indicates that a significant portion of shares held by the second-largest shareholder, Huang Qianyi, has been judicially frozen due to a debt contract dispute, but this will not impact the company's control or operations significantly [1][2]. Group 1: Shareholder Information - Huang Qianyi holds 27,219,439 shares, representing 6.426% of the total share capital of Huili Pharmaceutical [2]. - A total of 21,711,132 shares held by Huang have been frozen, accounting for 79.763% of his holdings and 5.125% of the company's total shares [2]. - The freezing of shares is related to a private lending dispute with Jin Zuping, who has sought property preservation through the court [2]. Group 2: Company Performance - For the first half of 2025, Huili Pharmaceutical reported revenue of approximately 453 million yuan, a decrease of 14.86% year-on-year [3]. - The net profit attributable to shareholders was approximately -80.72 million yuan, representing a decline of 223.78% year-on-year, marking the first loss in interim performance since the company went public [3]. - The basic earnings per share were reported as a loss of 0.19 yuan [3]. Group 3: Market Performance - As of September 22, the stock price of Huili Pharmaceutical closed at 24.82 yuan per share, reflecting a 1.06% increase on that day, with a total market capitalization of 10.51 billion yuan [4]. - Since the beginning of 2025, the stock price has increased by 68.39% [4].

证券代码：688553 证券简称：汇宇制药 公告编号：2025-076 四川汇宇制药股份有限公司 持股 5%以上股东部分股份被轮候冻结的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 四川汇宇制药股份有限公司（以下简称"公司"）股东黄乾益直接持有公 司股份 27,219,439 股，占公司总股本比例为 6.426%。 2025 年 9 月 19 日，股东黄乾益先生持有公司股份被四川天府新区人民 法院司法轮候冻结 280,000 股。截至本公告披露日，股东黄乾益先生持 有公司股份中 21,711,132 股被司法冻结，前述股份均处于司法冻结/司法 标记状态。本次披露的轮候冻结事项不会对公司日常经营与管理造成影 响。 | | | 二、股东股份累计被冻结情况 截至公告披露日，上述股东累计被冻结股份情况如下： | 股东名称 | 持 数 | 股 | 量 | 持股比例 | 累计被司法冻结数 | 占其所持股 | 占公司总股 | | --- | --- | --- | --- | --- | --- | --- | ...

Group 1 - The core point of the article is that Huyou Pharmaceutical has reported that a significant portion of its shareholder's shares has been judicially frozen, which may impact the company's stock performance and investor sentiment [1] - As of the announcement date, shareholder Huang Qianyi has approximately 21.71 million shares frozen, accounting for about 79.76% of his holdings and 5.13% of the company's total share capital [1] - The company's revenue composition for the year 2024 is heavily weighted towards pharmaceuticals, with 99.18% coming from this sector and only 0.82% from other businesses [1] Group 2 - Huyou Pharmaceutical's current market capitalization is 10.5 billion yuan [1]

Investment Rating - The report maintains a "Recommended" investment rating for the pharmaceutical industry as of September 21, 2025 [1] Core Insights - The trend of Chinese innovative drugs going global is a significant industry trend, with a notable increase in License-out transactions in the first half of 2025, surpassing the total number for 2024 by over half and increasing transaction amounts by 16% [2] - The report highlights the importance of structural opportunities within the industry, emphasizing the need to select high-quality companies amidst the competitive landscape [2] - The report notes that while the trend of innovative drugs going abroad continues, concerns have arisen due to fewer major transactions and proposed U.S. regulations affecting Chinese drug licensing [2] - The report identifies significant breakthroughs in small nucleic acid drugs, particularly in chronic disease areas such as hypertension, with notable partnerships and potential milestone payments [3] - The report discusses promising clinical data from Chinese ADCs presented at the World Lung Cancer Conference, showcasing competitive advantages in efficacy and safety [4] - The report mentions the advancements in GLP-1 analogs for weight loss, with ongoing developments from both multinational corporations and domestic companies [5] - The CXO sector is expected to gradually recover, driven by an increase in orders and favorable policy changes [6] - The report outlines the completion of expert reviews for the 2025 medical insurance negotiation and commercial insurance innovative drug directories, indicating potential impacts on participating companies [7] Summary by Sections 1. Pharmaceutical Market Tracking - The pharmaceutical industry index has underperformed compared to the CSI 300 index, with a recent weekly decline of 2.07% [22] - Over the past month, the industry has lagged behind the CSI 300 index by 7.79 percentage points [23] 2. Pharmaceutical Sector Trends and Valuation - The current PE (TTM) for the pharmaceutical industry index is 39.77, above the five-year historical average of 31.50 [48] 3. Recent Research Achievements - The report includes various recent research outputs, highlighting the ongoing focus on innovative drug development and market opportunities [50] 4. Recent Industry Policies and News - The report details recent policy updates from the National Medical Insurance Administration regarding drug directory adjustments and the implications for the industry [52][54]

资料显示，四川汇宇制药股份有限公司位于四川省内江市市中区汉阳路333号3幢，成立日期2010年10月 12日，上市日期2021年10月26日，公司主营业务涉及肿瘤领域药物和复杂注射剂药物的研发、生产和国 内外销售。主营业务收入构成为：药品销售97.27%，技术服务1.66%，其他1.07%。 从基金十大重仓股角度 数据显示，大成基金旗下1只基金重仓汇宇制药。大成医药健康股票A（012045）二季度持有股数43.15 万股，占基金净值比例为4.07%，位居第十大重仓股。根据测算，今日浮亏损失约56.09万元。 大成医药健康股票A（012045）成立日期2021年9月16日，最新规模1.53亿。今年以来收益36.96%，同 类排名1224/4222；近一年收益52.07%，同类排名1953/3805；成立以来亏损22.93%。 9月19日，汇宇制药跌5.06%，截至发稿，报24.41元/股，成交1.46亿元，换手率1.69%，总市值103.40亿 元。 大成医药健康股票A（012045）基金经理为杨挺。 截至发稿，杨挺累计任职时间11年89天，现任基金资产总规模12.81亿元，任职期间最佳基金回报 77.63%， ...

注：本文系新闻报道，不构成投资建议，股市有风险，投资需谨慎。 汇宇制药9月18日大宗交易平台出现一笔成交，成交量12.50万股，成交金额331.00万元，大宗交易成交 价为26.48元，相对今日收盘价溢价2.99%。该笔交易的买方营业部为西南证券股份有限公司陕西分公 司，卖方营业部为中邮证券有限责任公司西安开元路证券营业部。 进一步统计，近3个月内该股累计发生5笔大宗交易，合计成交金额为7828.84万元。 9月18日汇宇制药大宗交易一览 | 成交量 | 成交金额 | 成交价格 | 相对当日收盘折 | 买方营业部 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | | （万股） | （万元） | （元） | 溢价（%） | | | | 12.50 | 331.00 | 26.48 | 2.99 | 西南证券股份有限 | 中邮证券有限责任公司西安 | | | | | | 公司陕西分公司 | 开元路证券营业部 | 证券时报·数据宝统计显示，汇宇制药今日收盘价为25.71元，上涨4.85%，日换手率为5.34%，成交额为 4.76亿元，全天主力资金净流入439.19万元， ...

Group 1 - A total of 83 stocks experienced block trades in the A-share market on September 18, with a total transaction value of 11.257 billion yuan [1] - The top three stocks by transaction value were Pudong Development Bank (6.368 billion yuan), Shenghong Technology (3.073 billion yuan), and Haoyuan Pharmaceutical (276 million yuan) [1] - Among the stocks, 21 were traded at par, 8 at a premium, and 54 at a discount; the highest premium rates were for Bangyan Technology (12.72%), Pudong Development Bank (3.29%), and Huayu Pharmaceutical-W (2.99%) [1] Group 2 - The top stocks by institutional buy amounts included Shenghong Technology (2.499 billion yuan), Dameng Data (70.342 million yuan), and Yinzhijie (54.357 million yuan) [1] - The top stocks by institutional sell amounts were Sanhua Intelligent Controls (9.11 million yuan), New Industry (7.968 million yuan), and Hailiang Co. (4.9551 million yuan) [2]

Group 1 - The Shanghai Stock Exchange's Innovation Value Index (950333) rose by 1.85%, with notable stock performances including Nanya New Materials (688519) up 17.07%, and Xinan Century (688201) up 14.07% [1] - Nearly 400 foreign institutions have conducted intensive research on A-share listed companies, with a total of around 1800 research instances, indicating sustained interest in Chinese assets [1] - Foreign institutions are focusing on high-end manufacturing and technological innovation sectors, particularly in industrial machinery, electrical equipment, electronic instruments, and healthcare [1] Group 2 - According to CITIC Securities, AI technology is rapidly integrating into various industries, leading to a continuous increase in demand for computing power due to large-scale AI models and massive data [1] - The semiconductor industry is a key battleground in the new wave of technological transformation, with semiconductor equipment being crucial for this sector [1] - The ongoing technological transformation is expected to accelerate domestic substitution, with significant replacement potential in areas with low domestic production rates [1] Group 3 - From a global liquidity perspective, the limited rise in U.S. inflation and a weakening job market have strengthened market expectations for a Federal Reserve interest rate cut [2] - The weakening U.S. dollar index may support the performance of A-shares, enhancing the outlook for the market [2] - The Innovation Value ETF closely tracks the Shanghai Stock Exchange's Innovation Value Index, which includes 100 companies with strong technological innovation capabilities, low valuations, and good profit quality [2]

9月15日，汇宇制药涨0.84%，成交额1.87亿元。两融数据显示，当日汇宇制药获融资买入额2550.87万 元，融资偿还3591.99万元，融资净买入-1041.12万元。截至9月15日，汇宇制药融资融券余额合计2.08 亿元。 融资方面，汇宇制药当日融资买入2550.87万元。当前融资余额2.08亿元，占流通市值的2.65%，融资余 额超过近一年80%分位水平，处于高位。 融券方面，汇宇制药9月15日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00元； 融券余量0.00股，融券余额0.00元，超过近一年90%分位水平，处于高位。 资料显示，四川汇宇制药股份有限公司位于四川省内江市市中区汉阳路333号3幢，成立日期2010年10月 12日，上市日期2021年10月26日，公司主营业务涉及肿瘤领域药物和复杂注射剂药物的研发、生产和国 内外销售。主营业务收入构成为：药品销售97.27%，技术服务1.66%，其他1.07%。 截至6月30日，汇宇制药股东户数1.63万，较上期减少11.81%；人均流通股21131股，较上期增加 25.85%。2025年1月-6月，汇宇制药实现营业收入4. ...

证券代码：688553 证券简称：汇宇制药 公告编号：2025-073 四川汇宇制药股份有限公司 2025年第一次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的 真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 本次会议是否有被否决议案：无 一、会议召开和出席情况 （三）出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及其持有表决权数量的情 况： ■ （四）表决方式是否符合《公司法》及公司章程的规定，大会主持情况等。 本次会议由公司董事会召集，由公司董事长丁兆先生主持，采用现场投票和网络投票相结合的方式召 开。本次会议的召集、召开程序符合《公司法》、《证券法》、《公司章程》的规定。 （五）公司董事、监事和董事会秘书的出席情况 1、公司在任董事8人，出席8人，现场结合通讯方式出席8人； 二、议案审议情况 （一）非累积投票议案 1、议案名称：《关于取消监事会、修订〈公司章程〉及其附件并办理工商变更登记的议案》 审议结果：通过 表决情况： ■ 2、议案名称：《关于制定和修订部分公司治理制度的议案》 2.01、议案名称：《关于修 ...